Smith & Nephew SNATS (NYSE:SNN) Sees Strong Trading Volume – What’s Next?

Posted by Brian Himes on May 26th, 2026

Smith & Nephew SNATS, Inc. (NYSE:SNN – Get Free Report) saw strong trading volume on Tuesday . 824,135 shares were traded during mid-day trading, a decline of 18% from the previous session’s volume of 1,003,425 shares.The stock last traded at $30.52 and had previously closed at $30.53.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on SNN shares. Sanford C. Bernstein set a $31.85 price target on shares of Smith & Nephew SNATS in a research note on Monday, May 11th. Canaccord Genuity Group cut their price objective on Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating on the stock in a research report on Monday, May 11th. Wall Street Zen downgraded Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Weiss Ratings restated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research note on Monday, April 20th. Finally, The Goldman Sachs Group restated a “buy” rating on shares of Smith & Nephew SNATS in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, Smith & Nephew SNATS presently has an average rating of “Moderate Buy” and an average target price of $30.93.

Check Out Our Latest Analysis on SNN

Smith & Nephew SNATS Stock Down 0.4%

The company’s fifty day moving average price is $31.86 and its 200-day moving average price is $33.11. The company has a current ratio of 2.57, a quick ratio of 1.25 and a debt-to-equity ratio of 0.60.

Smith & Nephew SNATS (NYSE:SNN – Get Free Report) last posted its quarterly earnings results on Tuesday, February 17th. The medical equipment provider reported $29.55 earnings per share for the quarter. The company had revenue of $1.60 billion during the quarter. Sell-side analysts predict that Smith & Nephew SNATS, Inc. will post 2.25 EPS for the current year.

Smith & Nephew SNATS Announces Dividend

The business also recently declared a dividend, which will be paid on Wednesday, May 27th. Stockholders of record on Friday, March 27th will be issued a dividend of $0.482 per share. The ex-dividend date is Friday, March 27th. This represents a dividend yield of 304.0%.

Hedge Funds Weigh In On Smith & Nephew SNATS

A number of hedge funds have recently bought and sold shares of SNN. Garner Asset Management Corp purchased a new position in Smith & Nephew SNATS in the fourth quarter worth about $27,000. Arax Advisory Partners increased its position in shares of Smith & Nephew SNATS by 142.6% during the fourth quarter. Arax Advisory Partners now owns 968 shares of the medical equipment provider’s stock valued at $32,000 after acquiring an additional 569 shares in the last quarter. Advisors Asset Management Inc. purchased a new position in Smith & Nephew SNATS in the 4th quarter worth approximately $36,000. Caitong International Asset Management Co. Ltd bought a new position in Smith & Nephew SNATS in the 3rd quarter valued at approximately $41,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in Smith & Nephew SNATS during the 4th quarter valued at $43,000. Institutional investors own 25.64% of the company’s stock.

About Smith & Nephew SNATS

(Get Free Report)

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.